Andrea Cippitelli

List of Publications by Year
in descending order

54	3,317	159358	155451
papers	citations	30 h-index	55 g-index

55	55	55	3015
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding. Journal of Neuroscience, 2002, 22, 9612-9617.	1.7	492
2	THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. Alcohol and Alcoholism, 2005, 40, 2-14.	0.9	305
3	3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-b]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism. Journal of Neuroscience, 2007, 27, 2718-2726.	1.7	232
4	Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. European Journal of Neuroscience, 2005, 21, 2243-2251.	1.2	135
5	Activation of Nuclear PPARÎ³ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking. Biological Psychiatry, 2011, 69, 642-649.	0.7	131
6	Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole â€“ LH 21. Neuropharmacology, 2006, 51, 358-366.	2.0	116
7	Dysregulation of Nociceptin/Orphanin FQ Activity in the Amygdala Is Linked to Excessive Alcohol Drinking in the Rat. Biological Psychiatry, 2008, 64, 211-218.	0.7	115
8	Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology, 2008, 198, 449-460.	1.5	103
9	Region-specific down-regulation of Crhr1 gene expression in alcohol-preferring msP rats following ad lib access to alcohol. Addiction Biology, 2007, 12, 30-34.	1.4	81
10	Activation of <scp>PPAR</scp>Î³ by Pioglitazone Potentiates the Effects of Naltrexone on Alcohol Drinking and Relapse in ms<scp>P</scp> Rats. Alcoholism: Clinical and Experimental Research, 2013, 37, 1351-1360.	1.4	77
11	Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. Pharmacology Biochemistry and Behavior, 2012, 100, 522-529.	1.3	76
12	Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. Psychopharmacology, 2010, 208, 417-426.	1.5	71
13	Endocannabinoid Regulation of Acute and Protracted Nicotine Withdrawal: Effect of FAAH Inhibition. PLoS ONE, 2011, 6, e28142.	1.1	70
14	Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect. Physiology and Behavior, 2004, 82, 63-68.	1.0	67
15	PPARÎ³ Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission. Neuropsychopharmacology, 2015, 40, 927-937.	2.8	67
16	Role of Feeding-Related Pathways in Alcohol Dependence: A Focus on Sweet Preference, NPY, and Ghrelin. Alcoholism: Clinical and Experimental Research, 2011, 35, 194-202.	1.4	66
17	The anandamide transport inhibitor AM404 reduces ethanol selfâ€administration. European Journal of Neuroscience, 2007, 26, 476-486.	1.2	64
18	Activation of Brain NOP Receptors Attenuates Acute and Protracted Alcohol Withdrawal Symptoms in the Rat. Alcoholism: Clinical and Experimental Research, 2011, 35, 747-755.	1.4	63

#	Article	IF	Citations
19	Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats. European Neuropsychopharmacology, 2014, 24, 1037-1045.	0.3	59
20	Role of the satiety factor oleoylethanolamide in alcoholism. Addiction Biology, 2016, 21, 859-872.	1.4	58
21	Alcohol-Induced Neurodegeneration, Suppression of Transforming Growth Factor-Î², and Cognitive Impairment in Rats: Prevention by Group II Metabotropic Glutamate Receptor Activation. Biological Psychiatry, 2010, 67, 823-830.	0.7	56
22	Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization. Journal of Neuroscience, 2015, 35, 11682-11693.	1.7	56
23	Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol, 2009, 43, 491-498.	0.8	52
24	Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. Psychopharmacology, 2010, 211, 367-375.	1.5	51
25	The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. Alcohol, 2011, 45, 567-576.	0.8	42
26	Role of a Genetic Polymorphism in the Corticotropin-Releasing Factor Receptor 1 Gene in Alcohol Drinking and Seeking Behaviors of Marchigian Sardinian Alcohol-Preferring Rats. Frontiers in Psychiatry, 2013, 4, 23.	1.3	42
27	Reversibility of object recognition but not spatial memory impairment following binge-like alcohol exposure in rats. Neurobiology of Learning and Memory, 2010, 94, 538-546.	1.0	39
28	Protection against alcohol-induced neuronal and cognitive damage by the PPARÎ³ receptor agonist pioglitazone. Brain, Behavior, and Immunity, 2017, 64, 320-329.	2.0	37
29	Binge-like ethanol consumption increases corticosterone levels and neurodegeneration whereas occupancy of type II glucocorticoid receptors with mifepristone is neuroprotective. Addiction Biology, 2014, 19, 27-36.	1.4	33
30	Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. Addiction Biology, 2013, 18, 644-653.	1.4	32
31	<scp>AT</scp>â€1001: a highâ€affinity Î±3Î²4 <scp>nAChR</scp> ligand with novel nicotineâ€suppressive pharmacology. British Journal of Pharmacology, 2015, 172, 1834-1845.	2.7	31
32	Melanin-concentrating hormone receptor 1 (MCH1-R) antagonism: Reduced appetite for calories and suppression of addictive-like behaviors. Pharmacology Biochemistry and Behavior, 2012, 102, 400-406.	1.3	30
33	Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology, 2012, 220, 87-96.	1.5	29
34	A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration. Scientific Reports, 2016, 6, 26594.	1.6	29
35	Hypericum perforatum CO2 Extract and Opioid Receptor Antagonists Act Synergistically to Reduce Ethanol Intake in Alcohol-Preferring Rats. Alcoholism: Clinical and Experimental Research, 2003, 27, 1554-1562.	1.4	25
36	Polymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats. Psychopharmacology, 2015, 232, 1083-1093.	1.5	25

#	Article	IF	Citations
37	Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice. Psychopharmacology, 2006, 185, 160-168.	1.5	20
38	Analysis of the distribution of spinal NOP receptors in a chronic pain model using NOPâ€eGFP knockâ€in mice. British Journal of Pharmacology, 2018, 175, 2662-2675.	2.7	20
39	Neurokinin 1 receptor blockade in the medial amygdala attenuates alcohol drinking in rats with innate anxiety but not in Wistar rats. British Journal of Pharmacology, 2015, 172, 5136-5146.	2.7	18
40	NOP Receptor Antagonists Decrease Alcohol Drinking in the Dark in C57BL/6J Mice. Alcoholism: Clinical and Experimental Research, 2019, 43, 2167-2178.	1.4	18
41	NOP-Related Mechanisms in Pain and Analgesia. Handbook of Experimental Pharmacology, 2019, 254, 165-186.	0.9	18
42	Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats. Drug and Alcohol Dependence, 2015, 156, 126-132.	1.6	17
43	Pharmacological stress is required for the anti-alcohol effect of the Î±3Î²4* nAChR partial agonist AT-1001. Neuropharmacology, 2015, 93, 229-236.	2.0	16
44	NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice. Neuropharmacology, 2020, 170, 108029.	2.0	16
45	Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats. Pain, 2018, 159, 2179-2191.	2.0	15
46	In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential. Frontiers in Psychiatry, 2017, 8, 52.	1.3	14
47	The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies. CNS Drugs, 2021, 35, 591-607.	2.7	11
48	Potent and selective NOP receptor activation reduces cocaine selfâ€administration in rats by lowering hedonic set point. Addiction Biology, 2020, 25, e12844.	1.4	10
49	Highly Selective and Potent Î±4Î²2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats. Journal of Medicinal Chemistry, 2017, 60, 10092-10104.	2.9	9
50	PPARÎ±/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochemical Pharmacology, 2018, 157, 235-243.	2.0	9
51	Differential regulation of alcohol taking and seeking by antagonism at Î±4Î²2 and Î±3Î²4 nAChRs. Psychopharmacology, 2018, 235, 1745-1757.	1.5	8
52	Activation of the Nociceptin/Orphanin FQ system is unable to reverse CRF2 receptor mediated anorexia in the rat. Peptides, 2006, 27, 3284-3291.	1.2	6
53	PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats. Neuropharmacology, 2022, 211, 109045.	2.0	6
54	PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 119, 110599.	2.5	2